Attovia Therapeutics became a public company on August 6, 2026, pricing 17,000,000 shares at $17.00 - a $289.0 million gross raise that delivered $268.8 million in net proceeds before expenses and pushed the company's pro-forma cash, cash equivalents and marketable securities to $399.0 million. Eight trading days later, the stock sits at $19.86, up roughly 17% from the IPO price but down from a first-day intraday high of $21.90. The market capitalization is approximately $854.6 million on 43.0 million shares outstanding post-IPO. There is no operating quarter to summarize in the traditional sense: Attovia is a clinical-stage biopharmaceutical company, incorporated in December 2022, with three internally discovered product candidates - one in the clinic, two in IND-enabling studies - and zero product revenue.
The first quarter of 2026 - the most recent reported period before the IPO - is the cleanest read on what the company is spending and where. Research and development expense rose 41% year over year to $16.7 million, driven entirely by a $3.9 million increase in clinical, manufacturing and preclinical services as ATTO-1310, ATTO-3712 and ATTO-1091 moved through CRO and CMO work. General and administrative expense fell 24% to $3.2 million as the company stopped spending on public-company readiness work. Net loss for the quarter was $18.7 million, up 23% from a year ago, on a basic and diluted GAAP net loss per share of $4.49 (4,153,167 weighted-average shares, post the 1-for-9.29 reverse stock split effected July 29, 2026). Year-over-year, the company is bigger, more focused on the clinic, and burning cash at a rate that - combined with the IPO proceeds - management says will fund operations into 2029.
The investment case is not the quarterly income statement. It is the ATTOBODY platform, the early Phase 1 anti-IL-31 pruritus data, and the question of whether a clinical-stage biotech that priced its IPO on early tolerability and PK results can convert that into a Phase 2 readout in atopic dermatitis and chronic pruritus of unknown origin. Two of three product candidates - ATTO-2306 (IL-13/IL-31 bispecific) and ATTO-1091 (TL1A/IL-23/integrin α4β7 trispecific) - are not in the clinic yet. The IPO is a financing event that buys roughly two and a half years of runway, and the next two reads that matter are the Phase 1b ATTO-1310 efficacy expansion and the planned Phase 1 starts for ATTO-2306 and ATTO-1091 in the first half of 2027. With $399 million of pro-forma cash, no debt, and a clean structure after the conversion of all preferred stock at the IPO, the question is execution on the pipeline, not the balance sheet.